查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462605

2030年癌症支持治疗药物的市场预测：按癌症类型、支持治疗类型、药物类型、给药方法、分销管道和地区进行全球分析

Cancer Supportive Care Drugs Market Forecasts to 2030 - Global Analysis By Cancer Type, Supportive Care Type, Drug Type, Mode of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球癌症支持治疗药物市场规模为 214.6 亿美元，预计到 2030 年将达到 265.7 亿美元，预测期内复合年增长率为 2.4%。

癌症支持治疗药物是一种旨在控制癌症治疗的症状和副作用的药物，目的是改善患者的生活品质。这些药物针对化疗、放射线治疗和其他癌症治疗引起的各种问题，例如疼痛、噁心、疲劳和免疫抑制。这些药物包括止痛药、止吐药、造血生长因子和发炎药物。这些药物还可以透过减少不适和增加您的整体幸福感来帮助维持治疗顺从性。

根据美国国家癌症研究所的SEER资料库，2020年，未来20年癌症新病例数预计将达到2,840万例。

全球癌症盛行率不断上升

随着越来越多的人被诊断出患有癌症，对支持性护理药物来控制与癌症治疗相关的症状和副作用的需求不断增长。这种需求的增加源于缓解疼痛、噁心、疲劳和其他治疗相关併发症以及改善患者生活品质的需要。因此，製药公司渴望开发支持性护理药物并进行创新，推动市场开拓，以满足全球癌症患者日益增长的医疗需求。

副作用和毒性

癌症支持治疗药物的副作用包括噁心、呕吐、疲劳、贫血、神经病变和免疫抑制。此外，有些药物可能对肝臟和肾臟等器官有毒。这些副作用和毒性可能导致治疗中断、减重或停止，影响患者的依从性和治疗结果。此外，对副作用的担忧可能会阻止医疗保健专业人员开立某些药物，从而可能影响市场需求。

扩大安宁疗护服务

安宁疗护的整合强调了控制疼痛、噁心和其他副作用的重要性，并促进了支持性护理药物的开发和采用。安宁疗护服务的扩大将增加对缓解症状和改善癌症患者生活品质的药物的需求。这种扩张不仅改善了患者的福祉，而且还创造了一个环境，​​使製药公司可以创新并推出新的治疗方法满足接受癌症治疗的患者的独特需求，从而刺激市场成长。

医疗基础设施不足

设施、训练有素的人员和资源不足会导致诊断、治疗开始和癌症相关症状的适当管理的延迟。此外，基础设施薄弱往往会导致医疗保健服务的差异，对服务不足的人口造成不成比例的影响。如果没有足够的基础设施来支持全面的癌症治疗，对支持性护理药物的需求将无法得到满足，从而阻碍市场扩张并阻止患者接受基本治疗以缓解症状和改善生活品质。

COVID-19 的影响

COVID-19 的爆发对癌症支持治疗药物市场产生了重大影响。癌症筛检、诊断和治疗的延误以及医疗保健服务的中断正在影响对支持性护理药物的需求。此外，供应链中断和应对疫情的资源重新分配进一步加剧了市场动态的紧张。总体而言，这场大流行强调了有弹性的医疗保健系统的重要性，并强调了在提供癌症护理方面采用创新方法的必要性。

前列腺癌领域预计在预测期内规模最大

前列腺癌领域预计将出现良好的成长。在支持性癌症医学领域，应对摄护腺癌的挑战需要采取多方面的方法。前列腺癌的支持性治疗药物旨在减少治疗的副作用并提高患者的生活品质。此外，针对摄护腺癌特有症状和併发症（例如泌尿功能障碍和勃起功能障碍）的药物也可能发挥重要作用。这些药物的开发和供应对于增强前列腺癌患者的整体护理和福祉至关重要。

静脉注射药物领域预计在预测期内复合年增长率最高。

预计静脉注射药物细分市场在预测期内将以最高的复合年增长率成长。静脉注射药物透过将药物直接输送到血液中，确保快速有效的吸收，在支持性癌症治疗中发挥至关重要的作用。这些药物对于控制化疗引起的副作用（如噁心、呕吐、贫血、嗜中性白血球低下和疼痛）至关重要。这些药物提供有针对性的治疗，可以精确剂量和即时缓解，改善接受治疗的癌症患者的生活品质。

比最大的地区

预计亚太地区在预测期内将占据最大的市场占有率。癌症发生率正在增加，特别是在中国和印度等人口大国，这增加了对支持性护理药物来控制癌症治疗的症状和副作用的需求。此外，医疗基础设施的改善和癌症治疗意识的提高也有助于市场扩张。此外，製药公司和医疗机构之间的合作以及政府加强癌症护理服务的倡议正在进一步推动癌症支持治疗药物市场的成长。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高。高癌症发生率、先进的医疗基础设施以及对研发的重视等因素促成了这一增长。此外，有利的报销政策以及患者和医疗保健专业人员意识的提高正在推动对支持性护理药物的需求。北美专注于改善患者的治疗结果和生活质量，仍然是支持性癌症治疗药物开发和商业化的重要地区。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次研究资料
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 疾病的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球癌症支持治疗药物市场：依癌症类型分类

  • 乳癌
  • 肺癌
  • 摄护腺癌
  • 大肠直肠癌
  • 其他癌症类型

第六章全球癌症支持治疗药物市场：依支持治疗类型

  • 化疗引起的噁心和呕吐（CINV）的治疗
  • 贫血管理
  • 嗜中性白血球低下症的治疗
  • 骨转移的治疗
  • 疼痛管理
  • 疲劳管理
  • 其他支持性护理类型

第七章全球癌症支持治疗药物市场：依药物类型

  • 止吐药
  • 红血球生成刺激因子 (ESA)
  • 颗粒细胞增生因子(G-CSF)
  • 双磷酸盐
  • 非类固醇消炎剂(NSAID)
  • 皮质类固醇
  • 其他药物种类

第八章全球癌症支持治疗药物市场：依给药方法分类

  • 口腔医学
  • 注射药物
  • 外用药
  • 静脉注射药物
  • 其他管理方法

第九章全球癌症支持治疗药物市场：按分销管道

  • 医院药房
  • 零售药房
  • 网路药房
  • 癌症治疗中心
  • 其他分销管道

第十章全球癌症支持治疗药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Limited
  • F. Hoffmann-La Roche Limited
  • Bayer AG
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bristol Myers Squibb
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Daiichi Sankyo Company
Product Code: SMRC25656

According to Stratistics MRC, the Global Cancer Supportive Care Drugs Market is accounted for $21.46 billion in 2023 and is expected to reach $26.57 billion by 2030 growing at a CAGR of 2.4% during the forecast period. Cancer supportive care drugs are medications designed to manage the symptoms and side effects of cancer treatment, aiming to improve patients' quality of life. These drugs target various issues such as pain, nausea, fatigue, and immune suppression caused by chemotherapy, radiation therapy, or other cancer treatments. They include analgesics, antiemetics, hematopoietic growth factors, and anti-inflammatory agents. These drugs also assist in maintaining treatment adherence by reducing discomfort and enhancing overall well-being.

According to the SEER Database of the U.S. National Cancer Institute, 2020, in the next twenty years, there will likely be 28.4 million new instances of cancer.

Market Dynamics:

Driver:

Rising prevalence of cancer globally

With an increasing number of individuals diagnosed with cancer, there is a higher demand for supportive care drugs to manage symptoms and side effects associated with cancer treatments. This increased demand stems from the necessity to alleviate pain, nausea, fatigue, and other treatment-related complications, enhancing patients' quality of life. Consequently, pharmaceutical companies are motivated to develop and innovate supportive care drugs, driving market expansion to meet the growing healthcare needs of cancer patients worldwide.

Restraint:

Side effects and toxicity

Side effects of cancer supportive care drugs can include nausea, vomiting, fatigue, anaemia, neuropathy, and immunosuppression. Additionally, some drugs may pose risks of toxicity to organs such as the liver or kidneys. These side effects and toxicities can lead to treatment interruptions, dose reductions, or discontinuation, affecting patient adherence and treatment outcomes. Moreover, concerns about adverse effects may deter healthcare providers from prescribing certain drugs, impacting market demand.

Opportunity:

Expansion of palliative care services

Palliative care integration underscores the importance of managing pain, nausea, and other side effects, prompting the development and adoption of supportive care drugs. Expansion of palliative care services increases the demand for medications that alleviate symptoms and improve quality of life for cancer patients. This expansion not only enhances patient well-being but also creates a conducive environment for pharmaceutical companies to innovate and introduce new therapies tailored to address the unique needs of individuals undergoing cancer treatment, thereby fueling market growth.

Threat:

Inadequate healthcare infrastructure

Insufficient facilities, trained personnel, and resources lead to delays in diagnosis, treatment initiation, and proper management of cancer-related symptoms. Moreover, poor infrastructure often results in disparities in healthcare delivery, disproportionately affecting underserved populations. Without adequate infrastructure to support comprehensive cancer care, the demand for supportive care drugs remains unmet, hindering market expansion and depriving patients of essential treatments to alleviate symptoms and improve quality of life.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the cancer supportive care drugs market. Delays in cancer screenings, diagnosis, and treatment, alongside disruptions in healthcare services, have affected the demand for supportive care drugs. Additionally, supply chain disruptions and resource reallocation to address the pandemic have further strained market dynamics. Overall, the pandemic has underscored the importance of resilient healthcare systems and highlighted the need for innovative approaches to cancer care delivery.

The prostate cancer segment is expected to be the largest during the forecast period

The prostate cancer segment is estimated to have a lucrative growth. In the realm of cancer supportive care drugs, addressing the challenges of prostate cancer entails a multifaceted approach. Supportive care drugs for prostate cancer aim to mitigate treatment side effects and improve patients' quality of life. Additionally, drugs targeting prostate cancer-specific symptoms and complications, such as urinary issues or erectile dysfunction, may also play a crucial role. The development and availability of these drugs are pivotal in enhancing the holistic care and well-being of prostate cancer patients.

The intravenous drugs segment is expected to have the highest CAGR during the forecast period

The intravenous drugs segment is anticipated to witness the highest CAGR growth during the forecast period. Intravenous drugs play a pivotal role in cancer supportive care by delivering medications directly into the bloodstream, ensuring rapid and efficient absorption. These drugs are crucial for managing chemotherapy-induced side effects such as nausea, vomiting, anaemia, neutropenia, and pain. They offer targeted treatment, allowing for precise dosing and immediate relief, thereby enhancing the quality of life for cancer patients undergoing treatment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Increasing cancer prevalence, particularly in populous countries like China and India, drives demand for supportive care drugs to manage symptoms and side effects of cancer treatment. Additionally, improving healthcare infrastructure and rising awareness about cancer care contribute to market expansion. Moreover, collaborations between pharmaceutical companies and healthcare organizations, along with government initiatives to enhance cancer care services, further propel the growth of the cancer supportive care drugs market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and strong emphasis on research and development contribute to this growth. Moreover, favourable reimbursement policies and increasing awareness among both patients and healthcare providers drive demand for supportive care drugs. With a focus on improving patient outcomes and quality of life, North America remains a key region for the development and commercialization of cancer supportive care drugs.

Key players in the market

Some of the key players profiled in the Cancer Supportive Care Drugs Market include Amgen Inc., Johnson & Johnson, Pfizer Inc., Novartis International AG, Merck & Co. Inc., Teva Pharmaceutical Industries Limited, F. Hoffmann-La Roche Limited, Bayer AG, Eli Lilly and Company, AstraZeneca PLC, Bristol Myers Squibb, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, AbbVie Inc. and Daiichi Sankyo Company.

Key Developments:

In November 2023, AstraZeneca's Truqap in combination with Faslodex has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations. Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

In March 2022, Novartis received approval from the United States Food and Administration (FDA) for Pluvicto, developed for the treatment of adult patients with prostate cancer. The cancer supportive care drug by Novartis is specially designed for cancer patients that already have had other anti-cancer therapies.

Cancer Types Covered:

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Other Cancer Types

Supportive Care Types Covered:

  • Chemotherapy-induced Nausea & Vomiting (CINV) Management
  • Anaemia Management
  • Neutropenia Management
  • Bone Metastasis Management
  • Pain Management
  • Fatigue Management
  • Other Supportive Care Types

Drug Types Covered:

  • Anti-emetics
  • Erythropoiesis-stimulating Agents (ESAs)
  • Granulocyte Colony-stimulating Factors (G-CSFs)
  • Bisphosphonates
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Other Drug Types

Mode of Administrations Covered:

  • Oral Drugs
  • Injectable Drugs
  • Topical Drugs
  • Intravenous Drugs
  • Other Mode of Administrations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Cancer Treatment Centers
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Supportive Care Drugs Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Breast Cancer
  • 5.3 Lung Cancer
  • 5.4 Prostate Cancer
  • 5.5 Colorectal Cancer
  • 5.6 Other Cancer Types

6 Global Cancer Supportive Care Drugs Market, By Supportive Care Type

  • 6.1 Introduction
  • 6.2 Chemotherapy-induced Nausea & Vomiting (CINV) Management
  • 6.3 Anaemia Management
  • 6.4 Neutropenia Management
  • 6.5 Bone Metastasis Management
  • 6.6 Pain Management
  • 6.7 Fatigue Management
  • 6.8 Other Supportive Care Types

7 Global Cancer Supportive Care Drugs Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Anti-emetics
  • 7.3 Erythropoiesis-stimulating Agents (ESAs)
  • 7.4 Granulocyte Colony-stimulating Factors (G-CSFs)
  • 7.5 Bisphosphonates
  • 7.6 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.7 Corticosteroids
  • 7.8 Other Drug Types

8 Global Cancer Supportive Care Drugs Market, By Mode of Administration

  • 8.1 Introduction
  • 8.2 Oral Drugs
  • 8.3 Injectable Drugs
  • 8.4 Topical Drugs
  • 8.5 Intravenous Drugs
  • 8.6 Other Mode of Administrations

9 Global Cancer Supportive Care Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Cancer Treatment Centers
  • 9.6 Other Distribution Channels

10 Global Cancer Supportive Care Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen Inc.
  • 12.2 Johnson & Johnson
  • 12.3 Pfizer Inc.
  • 12.4 Novartis International AG
  • 12.5 Merck & Co. Inc.
  • 12.6 Teva Pharmaceutical Industries Limited
  • 12.7 F. Hoffmann-La Roche Limited
  • 12.8 Bayer AG
  • 12.9 Eli Lilly and Company
  • 12.10 AstraZeneca PLC
  • 12.11 Bristol Myers Squibb
  • 12.12 GlaxoSmithKline PLC
  • 12.13 Takeda Pharmaceutical Company Limited
  • 12.14 AbbVie Inc.
  • 12.15 Daiichi Sankyo Company

List of Tables

  • Table 1 Global Cancer Supportive Care Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Cancer Supportive Care Drugs Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 4 Global Cancer Supportive Care Drugs Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 5 Global Cancer Supportive Care Drugs Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 6 Global Cancer Supportive Care Drugs Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 7 Global Cancer Supportive Care Drugs Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 8 Global Cancer Supportive Care Drugs Market Outlook, By Supportive Care Type (2021-2030) ($MN)
  • Table 9 Global Cancer Supportive Care Drugs Market Outlook, By Chemotherapy-induced Nausea & Vomiting (CINV) Management (2021-2030) ($MN)
  • Table 10 Global Cancer Supportive Care Drugs Market Outlook, By Anaemia Management (2021-2030) ($MN)
  • Table 11 Global Cancer Supportive Care Drugs Market Outlook, By Neutropenia Management (2021-2030) ($MN)
  • Table 12 Global Cancer Supportive Care Drugs Market Outlook, By Bone Metastasis Management (2021-2030) ($MN)
  • Table 13 Global Cancer Supportive Care Drugs Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 14 Global Cancer Supportive Care Drugs Market Outlook, By Fatigue Management (2021-2030) ($MN)
  • Table 15 Global Cancer Supportive Care Drugs Market Outlook, By Other Supportive Care Types (2021-2030) ($MN)
  • Table 16 Global Cancer Supportive Care Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 17 Global Cancer Supportive Care Drugs Market Outlook, By Anti-emetics (2021-2030) ($MN)
  • Table 18 Global Cancer Supportive Care Drugs Market Outlook, By Erythropoiesis-stimulating Agents (ESAs) (2021-2030) ($MN)
  • Table 19 Global Cancer Supportive Care Drugs Market Outlook, By Granulocyte Colony-stimulating Factors (G-CSFs) (2021-2030) ($MN)
  • Table 20 Global Cancer Supportive Care Drugs Market Outlook, By Bisphosphonates (2021-2030) ($MN)
  • Table 21 Global Cancer Supportive Care Drugs Market Outlook, By Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
  • Table 22 Global Cancer Supportive Care Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 23 Global Cancer Supportive Care Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 24 Global Cancer Supportive Care Drugs Market Outlook, By Mode of Administration (2021-2030) ($MN)
  • Table 25 Global Cancer Supportive Care Drugs Market Outlook, By Oral Drugs (2021-2030) ($MN)
  • Table 26 Global Cancer Supportive Care Drugs Market Outlook, By Injectable Drugs (2021-2030) ($MN)
  • Table 27 Global Cancer Supportive Care Drugs Market Outlook, By Topical Drugs (2021-2030) ($MN)
  • Table 28 Global Cancer Supportive Care Drugs Market Outlook, By Intravenous Drugs (2021-2030) ($MN)
  • Table 29 Global Cancer Supportive Care Drugs Market Outlook, By Other Mode of Administrations (2021-2030) ($MN)
  • Table 30 Global Cancer Supportive Care Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Cancer Supportive Care Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 32 Global Cancer Supportive Care Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 33 Global Cancer Supportive Care Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 35 Global Cancer Supportive Care Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.